BioSpace News Archive

The Foundation for the National Institutes of Health has named Aviv Regev, Ph.D., winner of the 2020 Lurie Prize in Biomedical Sciences for laying the groundwork for the field of single-cell genomics and spearheading leading-edge technologies that enable a sharper perspective on human cells and applying them to revolutionize understanding of biology and disease.

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.00 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of $1.999 per pre-funded warrant

Almirall LLC today announced that the FDA approved an important update to the Seysara® label stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline

A member of the faculty at San Diego Academy of Regenerative Therapies (SDARTs) has published an important paper addressing pulmonary and respiratory therapies for patients who have suffered from the nCoV-2 Coronavirus.

Sengenics, the Functional Proteomics Company, announced today that it has entered into a research collaboration agreement with GlaxoSmithKline (GSK).

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tacrolimus Inhalation Powder for prophylaxis of lung allograft rejection. Tacrolimus Inhalation P

AppBus, an accelerator of business transformation, and Mednet, a provider of eClinical solutions for the global life sciences community, announced they have partnered together to address the rapidly evolving demands and requirements of clinical trials.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the first subject has been successfully dosed in a Phase 1b/2 clinical trial of dual glucagon-like peptide 1 receptor and the glucagon receptor agonist in China.

IMpassion031 data will be discussed with health authorities globally, including the U.S. Food and Drug Administration and the European Medicines Agency

The global market for tissue engineered skin substitutes is consolidated in nature as a large share of the market is being held by three leading players, namely Smith & Nephew, Molnlycke, and Acelity, states a new research study by Transparency Market Research.